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The life expectancy for cystic fibrosis (CF) patients has increased dramatically over the last 30 years. Although the overall cancer risk for
CF patients does not appear to be increased there is a marked increased risk of gastrointestinal malignancies especially in the post lung
transplant population. CF patients that do develop gastrointestinal malignancies do so at an earlier age and there is often a lag in the diagnosis
and management of these individuals.
We present a 39 year old male CF patient that underwent a colonoscopy for colon cancer screening and a large, near obstructing, villous
adenoma of his ileum was found. The polyp was removed successfully via endoscopy without incident and there was no evidence of
malignancy. An upper endoscopy revealed a long segment of Barrett's esophagus with no evidence of dysplasia.
We present this case as well as a detailed review of the literature on cancer risk in CF and a discussion of the mechanisms that may be
involved. We also present the risk of GI malignancies in non-CF patients as a guide on how to assess and manage the risk of GI malignancies
in this ever-changing patient population.
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Approximately 1 in every 2500 Caucasian newborns will
have cystic fibrosis (CF) resulting from a genetic mutation
in the cystic fibrosis transmembrane conductance regulatored by Elsevier B.V. All rights reserved.
Fig. 1. Ileal polyp; A) endoscopic view of the near obstructing polyp prior to
polypectomy, B) histopathological assessment revealed a villous adenoma
with no evidence of high grade dysplasia or malignancy.
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that population. This recessive disease has a carrier rate of
approximately 4% in the Caucasian population with the most
common mutation of CFTR being a deletion of the phenyla-
lanine residue at position 508 (ΔF508) which accounts for
about 67% of CF-causing gene mutations worldwide [1].
Improved therapy over the past three decades has allowed
for increased longevity in CF patients, increasing the like-
lihood that the health of CF patients will be affected by
disease states other than CF. In the past, screening of CF
patients for other disease states was limited due to the severity
of the CF symptoms, the inability of many patients to tolerate
screening procedures and the associated risks when subse-
quent interventions were required.
Over the last few decades it has become apparent that
those with CF have an increased risk of certain types of
cancer. Although the overall cancer risk in the CF population
has been shown to be approximately the same as in the
general population, they do have an increased risk of
developing certain forms of malignancies of the gastrointes-
tinal (GI) tract. The most common GI malignancies in the CF
population include both colorectal cancer and adenocarcino-
ma of the small intestine [2]. Not only do CF patients have a
higher risk of developing GI malignancies, they also present
at an earlier age and there is often a delay in making the
diagnosis. The average age of onset of GI malignancies
among North American and European CF patients was found
to be 32.2±12.6 years of age, compared to 58.2±14.3 years
of age in non-Hispanic whites [1].
The present case report highlights an asymptomatic
39 year old CF patient who was screened for colon cancer
due to positive family history of colorectal cancer (CRC) and
although a few small adenomas were noted in the colon, the
main finding was a near obstructing villous adenoma of the
ileum. To rule out polyps elsewhere in the GI tract an upper
endoscopy was performed and the patient was found to have
Barrett's esophagus without any biopsy evidence of dyspla-
sia. The patient had a normal small bowel follow through but
refused capsule endoscopy. In this report we review the case
in detail, discuss the increased incidence of GI malignancies
in CF and then review the possible factors that may be
involved in this increased risk of neoplasia in CF. We also
discuss an approach to GI screening and follow up of this
patient as well as others with CF.
2. Case report
A 39 year old male with CF (ΔF508 homozygous,
pancreatic insufficiency and chronic colonization with Pseu-
domonas aeruginosa) presented to the Outpatient Gastroen-
terology Clinic at the University of Calgary Medical Centre
inquiring about colon cancer screening.
His past history was significant for numerous complica-
tions of CF including recurrent pneumonias, pneumothoraces
and a pleurectomy. His only gastrointestinal problems in-
cluded a history of diarrhea (thought to be due to a high fatdiet and inadequate pancreatic enzyme replacement) as a
child. He also had common bile duct stones and subsequently
a cholecystectomy as well as mild gastro-esophageal reflux
for greater than 5 years which was effectively managed with
20 mg of omeprazole per day. He denied dysphagia, ody-
nophagia, early satiety, nausea, vomiting, change in weight or
bowel habit, GI blood loss, or abdominal pain and bloating.
His family history was significant in that his mother was
recently diagnosed with rectal cancer at the age of 61, a
maternal grandmother with Crohn's disease and a brother
who is deceased due to complications of CF. His abdominal
exam was unremarkable. His medications included omepra-
zole, salbutamol, Gluconorm (repaglinide), Pulmnozyme
Fig. 2. Barrett's esophagus; note the tongue like projections of the Barrett's
epithelium (arrows) and surrounding squamous epithelium.
Table 1
Cancer risk in CF and non-CF patients
SIR or RR (with CI)
CF patients (non-transplanted)
All sites [2] SIR; 1.1 (0.8–1.4)
Digestive SIR; 5.1 (3.2–7.6) [2],
6.4 (2.9–14.0) [1]
Non-digestive [2] SIR; 0.8 (0.6–1.0)
Esophagus [2] SIR; 5.4 (0.1–30.3)
Esophagus [1] SIR; 14.3 (1.4–148)
Stomach [2] SIR; 0.0 (0.0–8.9)
Small bowel [2] SIR; 24.8 (6.8–63.6)
Colon [2] SIR; 7.4 (3.7–13.2)
Liver [2] SIR; 4.1 (0.5–14.6)
Biliary tract/gallbladder [2] SIR; 39.0 (8.0–114.0)
CF patients (post transplanted)
All sites [2] SIR; 6.3 (3.4–10.8)
Digestive [2] SIR; 21.0 (5.8–54.2)
Small bowel [2] SIR; 143 (3.6–796.0)
Colon [2] SIR; 30.3 (3.7–109.0)
Liver [2] SIR; 76.9 (2.0–429.0)
Non-CF patients
Risk in 1st degree relative of
colon cancer patient [42]
SIR; colon cancer 2.24
(2.06–2.43)
Risk of colon cancer if sibling
diagnosed with colon cancer [42]
SIR; 2.03 (1.76–2.33)
Peutz–Jeghers [43] RR; small intestine
520 (220–1306),
colon 84 (47–137)
Lynch family cancer syndrome/
hereditary non-polyposis
colorectal cancer (HNPCC) [34]
SIR; 3.20 (2.39–4.19)
for cancers of the colon
and rectum
Ulcerative colitis [35] SIR; 4.1 (2.7–5.8) for
colon cancer
Crohn's disease [37] Pooled SIR; 2.5 (1.7–3.5)
for colon cancer
Pooled SIR; 27.1 (14.9–49.2)
for small bowel cancer
Celiac disease [38] SIR; 40.51 (1.03–225.68)
for small bowel lymphoma
SIR; 1.58 (0.72–2.99)
for all GI malignancies
Esophagitis SIR; 5.38 (3.01–8.87) [39],
6.0 (1.9–14) [40] for
adenocarcinoma of
the esophagus.
Barrett's esophagus SIR; 39.1 (20.2–68.3)
adenocarcinoma
of the esophagus [40]
SIR; standardized incidence ratio, CI; 95% confidence intervals, RR; relative
risk ratio.
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and a CF-specific multiple vitamin preparation (ADEKs).
The various modalities of colon cancer screening were
discussed with the patient in detail and after the risks and
benefits of each approach were reviewed the patient decided to
pursue colonoscopy. Colonoscopy revealed a normal looking
colon with a tiny 2–3 mm polyp in the ascending colon which
was removed by biopsy forceps. Approximately 15 cm up the
terminal ileum from the ileocecal valve, a large, near ob-
structing mass was encountered. This polypoid lesion was
approximately 2 cm wide and 3.5 cm in length and was
removed via endoscopic polypectomy without complications
(Fig. 1). The diminutive polyp was an adenoma without evi-
dence of high grade dysplasia. The polyp from the ileumwas a
villous adenoma alsowith no evidence of high grade dysplasia.
Three months later a repeat colonoscopy was performed
and a small piece of remaining ileal polyp was removed
without incident. The histology was identical to the previous
assessment. An upper endoscopy was performed to assess the
stomach and duodenum for polyps and none were identified.
However, 6 cm of Barrett's esophagus was noted (Fig. 2) with
no histological evidence of dysplasia. A small bowel follow
through was performed and was completely normal. The
patient refused a capsule endoscopy. A follow up colonoscopy
has been booked for 6 months and a repeat upper endoscopy
has been booked for 2 years from the last endoscopy for re-
assessment of the Barrett's esophagus. The patient refused
further genetic testing for genes associated with colon cancer.
3. Discussion
3.1. Risks and mechanisms of GI Cancer in CF patients
The overall cancer risk in the CF population has been
shown to be approximately the same as in the general pop-ulation. However, a few large studies have identified that CF
patients have an increased risk for developing GI malignan-
cies (see Table 1). In a 10-year study by Maisonneuve et al.
[2], CF patients developed significantly more GI cancers than
expected with a standardized incidence ratio (SIR) of 5.1 [2]
(see Table 1). More specifically there was an increased risk of
cancers of the small intestine (SIR; 24.8), colon (SIR;7.4),
biliary tract (SIR;39.0), liver (SIR;4.1), esophagus (SIR;5.4)
and pancreas (SIR;2.6) [2] (see Table 1). In a study from
1995, Neglia et al. [1] reported on approximately 25,000 CF
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and again a significantly increased risk of developing GI
malignancies was observed (see Table 1). CF patients also
develop GI malignancies at an earlier age (mean age
32.2 years [1]) and there is a marked increased risk in CF
patients between the age of 20 and 29 years (odds ratio; 20.2)
[1]. Since the average age of onset of GI malignancies in
North American and European non-Hispanic Caucasian
populations is approximately 58.2 years clearly those with
CF have earlier onset of GI malignancies [3].
Not only do CF patients have an increased risk of de-
veloping GI malignancies and are affected at an earlier age
but often there can be a delay in diagnosing these malig-
nancies [4]. This delay in diagnosis has not been thoroughly
studied and has been most often reported in case report
format. The cause of this delay has been attributed to the
numerous symptomatic GI problems that can also affect pa-
tients with CF. Furthermore, it appears that malignancies are
not high on the differential diagnosis due to the fact that most
of the patients are of a young age; and also likely due to the
limited knowledge that exists of their increased potential to
develop malignancies.
More specifically, in the present case, our patient had a
very high risk ileal polyp (based on polyp size and villous
changes), a small, low risk polyp of the colon and Barrett's
esophagus. Although over 50% of GI malignancies affect the
colon in CF patients, small bowel cancers are not uncom-
mon in the patient population as noted above [1,2]. CF has
been clearly recognized as a risk factor for developing small
bowel cancer [5]. There have been some reports specifically
of ileal cancers in CF patients and unfortunately in these cases
the lesion was not noted until autopsy or late in the disease
process [6–8].
Those with CF have long been known to have increased
problems with gastro-esophageal reflux [9–12]. Longstand-
ing GERD is associated with Barrett's esophagus and an
increased risk of esophageal cancer. Although the incidence
of Barrett's in the CF population has not been fully studied,
there have been case reports of Barrett's esophagus in CF
[13,14]. It is likely that this marked increase in GERD leads
to the increased risk of esophageal neoplasia in CF [1,2] (see
Table 1).
The pathophysiology involved in the increased risk of
GI malignancies in CF patients is unclear. Since CFTR is
expressed in much higher levels along the GI tract than in
adult lung epithelial cells and other tissues, a correlation
between levels of the mutated CFTR protein and an increased
risk of gastrointestinal malignancies has been postulated.
Mutations in the CFTR genemay lead to altered expression of
other genes including the mucin genes MUC 3, MUC 11 and
MUC 12 that are located adjacent to CFTR in the same
chromosome band 7q31 [2]. These mucins, which are
normally produced and excreted by the epithelial cell surface,
serve to protect the GI tract from injury, modulate bacterial
and cell adhesion, and mediate wound repair as well as other
processes critical in intestinal homeostasis. Altered regulationof these genes has been noted in colorectal carcinomas [15,16].
Altered mucin expression has been well described in CF with
an increased expression of MUC 5 in the lungs of CF patients
[17] and increased MUC 1, 2 and 3 expression by intestinal
epithelial cells in a mouse model of CF [18–20]. Interestingly,
treatment of bacterial overgrowth in this mouse model of CF
markedly reduced mucus, and MUC 2 and 3, production [21].
It has been postulated that altered mucin production (both
increases in certain forms aswell as decreases in certainMUC)
may be involved in the increased risk of GI inflammation and
malignancies seen in patients; however clear evidence for this
is lacking [2]. Interestingly the tumor markers CA 19-9 and
CA 125, which are also mucin-associated antigens, as well as
carcinoembryonic antigen (CEA), can be over expressed in CF
patients [22,23]. In addition, deficiencies in the omega-3 fatty
acid docosahexaenoic acid, selenium and vitamin E in CF
patients may also increase the risk as this essential fatty acid
and some of these antioxidants have been theorized to protect
against cancer [1,2].
Disease states of chronic GI inflammation, such as inflam-
matory bowel disease, Celiac disease and Helicobacter pylori
gastritis, are associated with an increased risk of GI malig-
nancies. Several studies have shown that patients with CF
may have ongoing intestinal inflammation affecting both the
small and large intestine [24–29]. At present it is unclear if
this chronic inflammation is due to pancreatic enzyme re-
placement, intestinal damage due to distal intestinal ob-
struction syndrome (DIOS), or other factors. Gut bacterial
load may also play a part; however, there appears to be
intestinal inflammation present prior to increased bacteria
counts [24,25]. High dose pancreatic enzyme replacement in
children, and more recently in adults, can be associated with
intestinal inflammation and in some settings can lead to
fibrosing colonopathy and/or strictures in the right colon
[24,25,30,31]. The exact cause of this inflammation is unclear
but some have proposed that it may, in part, be due to an
impaired intestinal barrier allowing leakage of pancreatic
enzymes into the surrounding tissues leading to diffuse tissue
injury and inflammation [32].
3.2. Cancer risk in non-CF patients
The cumulative lifetime risk of colon cancer in average
risk individuals in North America is about 6% and the risk of
colon cancer among first-degree relatives and siblings is
increased (SIR 1.47, 2.24, respectively) (see Table 1) [33].
Clearly some polyp syndromes have a very high risk of
developing cancer with some syndromes having an 80 to
100% risk. In Lynch family cancer syndrome/hereditary non-
polyposis colorectal cancer (HNPCC) the increased risk re-
sults in a SIR of 3.20 for cancers of the colon and rectum [34]
(see Table 1). Inflammatory bowel disease also increases the
risk of developing GI malignancies (ulcerative colitis; SIR
4.1 for CRC [35] (a meta-analysis noted a prevalence rate of
3.7% and a cumulative probability of 2% with disease dura-
tion up to 10 years to 18% with disease up to 30 years [36])
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SIR 27.1 for small intestinal cancer [37] (see Table 1). Celiac
disease has been found to be associated with an increased
risk of lymphoma in the small bowel (SIR 40.5) and all GI
malignancies (SIR 1.58) [38] (see Table 1).
In two studies assessing the risk of adenocarcinoma of the
esophagus in patients with esophagitis, the SIR was 5.38 and
6.0 [39,40] (see Table 1). The SIR for adenocarcinoma of the
esophagus in Barrett's is 39.1 [40]. Even with these risk
factors there is debate over the cost effectiveness of screening
Barrett's patients and those with longstanding reflux. At
present there are no current guidelines for screening patients
with esophagitis.
3.3. Comparing cancer risks in CF and non-CF patients
To date there are no clear guidelines if or how patients with
CF should be screened with respect to their risk of developing
a colorectal or small intestinal malignancy compared to
other at risk groups. It is difficult to directly compare different
disease states since earlier intestinal cancer studies did not
report SIR as did the main CF malignancy studies. Thus, in
the CF population with a SIR for the development of
esophageal cancer of 5.1 (3.2 to 7.6) (nearly identical to
those with esophagitis noted above) it would be appropriate
to screen these patients as one would those with known
esophagitis. Those with CF have a risk of developing small
intestinal cancer that appears to be lower than those with
Celiac disease (SIR 40.5) and similar to those with Crohn's
disease (CF; SIR=24.8, versus Crohn's SIR=27.1). At
present there are no guidelines for screening Celiac or
Crohn's disease patients for small intestinal malignancies.
These guidelines may change with the increased accuracy of,
and minimal invasiveness of, capsule endoscopy.
The SIR for CF patients for colon cancer was 7.4 and this
is markedly higher than the SIR for a first degree relative of a
patient that has colon cancer (SIR 1.47–2.03) and also higher
than Lynch/HNPCC syndrome (SIR 3.20), but markedly
lower than familial polyposis syndromes and likely lower
than UC. The current guidelines for colon cancer screening
for those with a genetic or clinical diagnosis of HNPCC or
who are at increased risk for HNPCC is that they should have
a colonoscopy every 1–2 years beginning at age 20–25 years,
or 10 years earlier than the youngest age of colon cancer
diagnosis in the family—whichever comes first [41]. It
should be noted in Table 1 that the risk of GI malignancies
increases dramatically in the post lung transplant population
(SIR for all digestive cancers, 21.0; small bowel, 143; colon,
30.3 and liver, 76.9) (based on a single report [2]). It should
be noted, that although some of the CF cancer risk studies
are very large and there are marked increased risks in cancer
development outlined in Table 1, these still translate into a
small number of cancers. In the largest study to date
(Maisonneuve et al. [2]) which followed 28,858 CF patients,
75 cancers were observed (versus 69.7 expected) including
23 digestive tract cancers (versus 4.5 expected) and in theNeglia et al. study [1] of approximately 53,000 patients 76
developed cancer (24 digestive tract cancers).
Colon cancer screening of those with CF should clearly
be considered on an individual basis in that screening ap-
proaches have their inherent risks. Routine screening for fecal
occult blood is reasonable for those with no added risk other
than CF, but due to the false positives inherent with this test it
would lead to increased numbers of colonoscopies being
performed on these individuals. Sigmoidoscopy and air
contrast barium enema are of lower risk but have a higher
miss rate than colonoscopy. Stool DNA testing and CT
colonography are still in the development stages as far as
screening tests, but at some point may well offer lower risk
options for these patients.
In summary, we have presented a 39 year old male patient
with CF with a family history of colon cancer. Upon screening
he was found to have small adenomas in his colon and a large,
near obstructing, villous adenoma of his ileum. Upper en-
doscopy revealed no further polyps, but he did have a long
segment of Barrett's esophagus. Several reports have
shown that patients with CF have a markedly increased risk
of developing cancers of the esophagus, small bowel and colon
which generally develops at younger age and there is often a
delay in the diagnosis. Furthermore, the risk appears to drama-
tically increase in the post lung transplant population. We feel
that this case and evidence in the literature highlights the need
to consider screening for GI malignancies in CF patients.
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